Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies. Founded in 2018, Synthekine is backed by investors that include Canaan Partners, Samsara BioCapital, and The Column Group and is headquartered in Menlo Park.